Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Lantern Pharma Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 4 pending office actions. These matters are distributed among 4 distinct examiners, which introduces a variety of perspectives into the prosecution process. The company's applications are being reviewed across 3 distinct art units, suggesting that the underlying technology spans several specialized administrative divisions within the patent office.
The busiest examiner for this portfolio is BRAUN, MADELINE E, who is currently responsible for 1 pending office action. Because the 4 pending office actions are spread across 4 distinct examiners, no single official dominates the company's current workload. This distribution requires the legal team to manage multiple simultaneous examination timelines and adapt to the different styles of each assigned examiner.
The presence of 3 distinct art units indicates that the portfolio faces a range of technical standards and precedents. Practitioners must tailor their arguments to the specific requirements of each unit. With 4 distinct examiners involved, the company has multiple paths toward allowance, but also faces a broader array of potential rejections. The current focus remains on resolving the 4 pending office actions within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18349256 | TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE | BRAUN, MADELINE E | 89d overdue |
| 17811812 | Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate | GUSSOW, ANNE | 77d |
| 18319919 | CANCER DRUG SENSITIVITY DETERMINING MARKERS | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18349256 | TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE | BRAUN, MADELINE E | 89d overdue |
| 17811812 | Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate | GUSSOW, ANNE | 77d |
| 18319919 | CANCER DRUG SENSITIVITY DETERMINING MARKERS | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1683 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18349256 | TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE | BRAUN, MADELINE E | 1624 | §103§112 | Final Rejection | 89d overdue | Pending | Jul 10, 2023 |
| 18319919 | CANCER DRUG SENSITIVITY DETERMINING MARKERS | POHNERT, STEVEN C | 1683 | §101§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 17811812 | Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate | GUSSOW, ANNE | 1683 | §101§103§112 | Final Rejection | 77d | Pending | Jul 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLantern Pharma Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Madeline E Braun has the most, with 1 of Lantern Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
